@Gralynchett
My comment re adding our own staff to assist GE in sales of our Trophon was not "my opinion". I usually read everything there is to read regarding my holdings and that was definitely something I read some time ago. I looked it up and this comment was in one of the brokers reports (posted on Nanosonic website) - Canaccord (dated 7/2/2013). This is not the only comment regarding our own sale team being a real drive of getting Trophon into places. Feel free to browse through these reports to get the feel of how it was. Extract below for you from report mentioned above.
> while GE is a major player in the US ultrasound market, with
over 35% market share and a well-established distribution network, we
were expecting this to result in more rapid penetration of the Trophon
into the US ultrasound market. However, as with all new products, it
has taken time to refine the sales process and also to ensure the right
organizational alignment and incentives are in place within GE. NAN’s
management has been very proactive in looking to improve the sales
effort within GE, including putting in place NAN’s own sales personnel
to help drive the sales effort.
>Infectious marketing: - the initial focus of GE’s marketing efforts has
been the end users (the sonographers). However it has become
apparent that Infection Control staff and OH&S officers can be key
advocates and decision makers with regards to site purchases of the
Trophon and turn the device from a “nice to have” to a “must have”.
NAN’s own sales personnel have had very good success in closing
sales by targeting their own and GE’s sales efforts to these individuals.
NAN Price at posting:
$1.65 Sentiment: Buy Disclosure: Held
(20min delay)